Sign in Subscribe
Cancer research

Breakthrough in Leukemia Research: Immunotherapy-driven Bone Marrow Niche Remodeling

Strategic Insights

— 1 min read

Research conducted at Johns Hopkins University has shed light on the effects of immunotherapy on bone marrow interactions in patients with acute myeloid leukemia (AML). The study employed a multiomic approach, combining single-cell RNA sequencing with single-cell spatial transcriptomics, to analyze the interactions between leukemia cells and immune cells post-immunotherapy treatment. The findings suggest that immunotherapy may alter signaling pathways between leukemia and immune cells, potentially contributing to clinical response. This groundbreaking research may inform therapeutic strategies for AML.

Key Takeaways:

  • The study employed a multiomic approach to examine bone marrow interactions in patients with AML treated with pembrolizumab and decitabine.
  • The research aimed to quantify cell-cell distances at the edge level to enable more accurate tumor microenvironment analysis.
  • Single-cell spatial transcriptomics revealed global and local immune cell enrichment near leukemia cells post-pembrolizumab treatment, potentially linked to clinical response.
  • Immunotherapy-driven bone marrow niche remodeling may be a critical component of leukemia treatment.
  • The study integrated single-cell RNA sequencing with single-cell spatial transcriptomics to address read-depth limitations and improve tumor microenvironment analysis.
  • Researchers used extensively trained nuclear and membrane segmentation models to achieve precise transcript assignment and deep learning-based image analysis.
  • The study provides insights into immune interactions in AML and may inform therapeutic strategies.
  • Financial supporters for this research include Intramural Research Programs of the NCI Center for Cancer Research, National Institutes of Health (NIH) - USA, Intramural Research Programs of the NHLBI, NIH National Institute of Allergy & Infectious Diseases (NIAID), NIH National Institute of General Medical Sciences (NIGMS).

Statistics:

  • 11/28: The study was published in Science Advances, volume 11, issue 28.
  • Baltimore, USA: The research was conducted at Johns Hopkins University.
  • AML cases: The study focused on acute myeloid leukemia (AML) patients.
  • Immunotherapy-treated patients: The research included patients treated with pembrolizumab and decitabine.
  • Sample size: The study included a sample size of a undisclosed number of patients.
  • Read-depth limitations: The research integrated single-cell RNA sequencing with single-cell spatial transcriptomics to address read-depth limitations.

Sources:

  • NewsRx. New Leukemia Study Findings Have Been Reported by Researchers at Johns Hopkins University (Single-cell Spatial Transcriptomics Reveals Immunotherapy-driven Bone Marrow Niche Remodeling In Aml). Hematology Week. August 4, 2025; p 2825.
  • Science Advances. Single-cell Spatial Transcriptomics Reveals Immunotherapy-driven Bone Marrow Niche Remodeling In Aml. 2025;11(28).
  • Johns Hopkins University. Department of Biostatistics, Bloomberg Sch Publ Hlth.

Read more